Brightsurf Science News & Current Events

December 02, 2000
Significant survival benefit shown with MabThera and chop chemotherapy in aggressive non-Hodgkin's lymphoma
Roche today announced positive interim results from a Phase III study evaluating the combination use of MabThera (rituximab) and CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy in previously- untreated patients with aggressive non-Hodgkin's lymphoma (NHL).

Antibody-targeted chemotherapy-induced remission and stem-cell transplantation prolong disease-free survival for leukemia patients
Patients with acute myeloid leukemia who achieve remission with the antibody-targeted chemotherapy agent Mylotarg™ have prolonged disease-free survival following stem cell transplantation according to research to be presented at the annual meeting of the American Society of Hematology.

People are poor at cross-race facial recognition because they concentrate on racial features rather than individual features, according to new study
Why do people of one racial group fail to recognize faces from another racial group? is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to